Landiolol for Managing Atrial Fibrillation in Intensive Care

Overview

Journal Eur Heart J Suppl

Publisher Oxford University Press

Date 2018 Sep 7

PMID 30188960

Citations 9

Authors

Sebastian Rehberg

Michael Joannidis

Tony Whitehouse

Andrea Morelli

Affiliations

Soon will be listed here.

Abstract

Landiolol is an injectable ultrashort acting beta-blocker with high beta1 selectivity indicated for heart rate control of atrial fibrillation in the emergency and critical care setting. Accordingly, landiolol is associated with a significantly reduced risk of arterial hypotension and negative inotropic effects. Based on this particular profile along with the clinical experience in Japan for more than a decade landiolol represents a promising agent for the management of elevated heart rate and atrial fibrillation in intensive care patients even with catecholamine requirements. This article provides a review and perspective of landiolol for heart rate control in intensive care patients based on the current literature.

Citing Articles

Mortality in septic patients treated with short-acting betablockers: a comprehensive meta-analysis of randomized controlled trials.

Alexandru M, Niewald P, Kruger S, Borgstedt R, Whitehouse T, Singer M Crit Care. 2024; 28(1):392.

PMID: 39605034 PMC: 11603935. DOI: 10.1186/s13054-024-05174-w.

The Impact of Chronic Oral Beta-Blocker Intake on Intravenous Bolus Landiolol Response in Hospitalized Intensive Care Patients with Sudden-Onset Supraventricular Tachycardia-A Post Hoc Analysis of a Cross-Sectional Trial.

Eibensteiner F, Mosor E, Tihanyi D, Anders S, Kornfehl A, Neymayer M Pharmaceutics. 2024; 16(6).

PMID: 38931959 PMC: 11207374. DOI: 10.3390/pharmaceutics16060839.

An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation.

Floria M, Oancea A, Morariu P, Burlacu A, Iov D, Chiriac C Pharmaceutics. 2024; 16(4).

PMID: 38675178 PMC: 11054558. DOI: 10.3390/pharmaceutics16040517.

Hemodynamic and Rhythmologic Effects of Push-Dose Landiolol in Critical Care-A Retrospective Cross-Sectional Study.

Schnaubelt S, Eibensteiner F, Oppenauer J, Tihanyi D, Neymayer M, Brock R Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259286 PMC: 9967759. DOI: 10.3390/ph16020134.

Relationship between red blood cell distribution width-to-albumin ratio and outcome of septic patients with atrial fibrillation: a retrospective cohort study.

Gu Y, Yang D, Huang Z, Chen Y, Dai Z BMC Cardiovasc Disord. 2022; 22(1):538.

PMID: 36494633 PMC: 9733276. DOI: 10.1186/s12872-022-02975-1.

References

Yoshida Y, Hongo T, Sakamoto A, Ogawa R . Successful management of tachycardiac atrial fibrillation in a septic patient with landiolol. Anesth Analg. 2004; 100(1):294. DOI: 10.1213/01.ANE.0000140814.28118.6F. View

Yoshida Y, Terajima K, Sato C, Akada S, Miyagi Y, Hongo T . Clinical role and efficacy of landiolol in the intensive care unit. J Anesth. 2008; 22(1):64-9. DOI: 10.1007/s00540-007-0573-3. View

Hagiwara S, Iwasaka H, Maeda H, Noguchi T . Landiolol, an ultrashort-acting beta1-adrenoceptor antagonist, has protective effects in an LPS-induced systemic inflammation model. Shock. 2008; 31(5):515-20. DOI: 10.1097/SHK.0b013e3181863689. View

Noveanu M, Breidthardt T, Reichlin T, Gayat E, Potocki M, Pargger H . Effect of oral β-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study. Crit Care. 2010; 14(6):R198. PMC: 3219994. DOI: 10.1186/cc9317. View

Rudiger A . Beta-block the septic heart. Crit Care Med. 2010; 38(10 Suppl):S608-12. DOI: 10.1097/CCM.0b013e3181f204ca. View

Balik M, Rulisek J, Leden P, Zakharchenko M, Otahal M, Bartakova H . Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock. Wien Klin Wochenschr. 2012; 124(15-16):552-6. DOI: 10.1007/s00508-012-0209-y. View

Schmittinger C, Dunser M, Torgersen C, Luckner G, Lorenz I, Schmid S . Histologic pathologies of the myocardium in septic shock: a prospective observational study. Shock. 2013; 39(4):329-35. DOI: 10.1097/SHK.0b013e318289376b. View

Nagai R, Kinugawa K, Inoue H, Atarashi H, Seino Y, Yamashita T . Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). Circ J. 2013; 77(4):908-16. DOI: 10.1253/circj.cj-12-1618. View

Walkey A, Greiner M, Heckbert S, Jensen P, Piccini J, Sinner M . Atrial fibrillation among Medicare beneficiaries hospitalized with sepsis: incidence and risk factors. Am Heart J. 2013; 165(6):949-955.e3. PMC: 3695631. DOI: 10.1016/j.ahj.2013.03.020. View

10.

Adachi T, Sato A, Baba M, Hiraya D, Hasegawa T, Kuroki K . Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure. Heart Vessels. 2013; 29(4):464-9. DOI: 10.1007/s00380-013-0377-3. View

11.

Morelli A, Donati A, Ertmer C, Rehberg S, Kampmeier T, Orecchioni A . Microvascular effects of heart rate control with esmolol in patients with septic shock: a pilot study. Crit Care Med. 2013; 41(9):2162-8. DOI: 10.1097/CCM.0b013e31828a678d. View

12.

Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S . Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013; 310(16):1683-91. DOI: 10.1001/jama.2013.278477. View

13.

Walkey A, Hammill B, Curtis L, Benjamin E . Long-term outcomes following development of new-onset atrial fibrillation during sepsis. Chest. 2014; 146(5):1187-1195. PMC: 4219336. DOI: 10.1378/chest.14-0003. View

14.

Seki Y, Jesmin S, Shimojo N, Islam M, Rahman M, Khatun T . Significant reversal of cardiac upregulated endothelin-1 system in a rat model of sepsis by landiolol hydrochloride. Life Sci. 2014; 118(2):357-63. DOI: 10.1016/j.lfs.2014.04.005. View

15.

Makrygiannis S, Margariti A, Rizikou D, Lampakis M, Vangelis S, Ampartzidou O . Incidence and predictors of new-onset atrial fibrillation in noncardiac intensive care unit patients. J Crit Care. 2014; 29(4):697.e1-5. DOI: 10.1016/j.jcrc.2014.03.029. View

16.

Ogura Y, Jesmin S, Yamaguchi N, Oki M, Shimojo N, Islam M . Potential amelioration of upregulated renal HIF-1alpha-endothelin-1 system by landiolol hydrochloride in a rat model of endotoxemia. Life Sci. 2014; 118(2):347-56. DOI: 10.1016/j.lfs.2014.05.007. View

17.

. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). Circ J. 2014; 78(8):1997-2021. DOI: 10.1253/circj.cj-66-0092. View

18.

Kuipers S, Klein Klouwenberg P, Cremer O . Incidence, risk factors and outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review. Crit Care. 2014; 18(6):688. PMC: 4296551. DOI: 10.1186/s13054-014-0688-5. View

19.

Tochikubo J, Adachi Y, Ejima T, Numaguchi A, Matsuda N, Sato S . Landiolol reduces hemodynamic responses to bronchoscopy-assisted suctioning in intubated ICU patients. J Intensive Care. 2014; 2(1):6. PMC: 4267460. DOI: 10.1186/2052-0492-2-6. View

20.

Hifumi T, Kato H, Koido Y, Kawakita K, Kuroda Y . Safety and effective use of landiolol in the ICU. J Intensive Care. 2014; 2(1):16. PMC: 4267602. DOI: 10.1186/2052-0492-2-16. View